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Purpose: To compare metabolic effects of modified release hydrocortisone (MR-HC) with
standard hydrocortisone (HC) therapies in adults with Adrenal Insufficiency (AI).
Methods: Adult patients (n = 12) with AI, established on HC therapy, were recruited from
Endocrinology clinics at University Hospitals Coventry and Warwickshire (UHCW), UK.
Baseline (HC) metabolic assessments included fasting serum HbA1C, lipid and thyroid
profiles, accurate measures of body composition (BodPod), and 24-h continuous
measures of energy expenditure including Sleeping Metabolic Rate (SMR) using indirect
calorimetry within the Human Metabolism Research Unit, UHCW. All participants then
switched HC to MR-HC with repeat (MR-HC) metabolic assessments at 3 months.
Paired-sample t-tests were used for data comparisons between HC and MR-HC
assessments: P-value <0.05 was considered significant.
Results: Following exclusion of 2 participants, analyses were based on 10 participants.
Compared with baseline HC data, following 3 months of MR-HC therapy mean fat mass
reduced significantly by −3.2 kg (95% CI: −6.0 to −0.4). Mean (SD) baseline HC fat mass
vs repeat MR-HC fat mass: 31.9 kg (15.2) vs 28.7 kg (12.8) respectively, P = 0.03. Mean
SMR increased significantly by +77 kcal/24 h (95% CI: 10–146). Mean (SD) baseline HC
SMR vs repeat MR-HC SMR: 1,517 kcal/24 h (301) vs 1,594 kcal/24 h (344) respectively,
P = 0.03. Mean body fat percentage reduced significantly by −3.4% (95% CI: −6.5 to
−0.2). Other measures of body composition, energy expenditure, and biochemical
analytes were equivalent between HC and MR-HC assessments.
Conclusions: In adults with AI, switching from standard HC to MR-HC associates with
early metabolic benefits of reduced fat mass and increased SMR.
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Adrenal insufficiency (AI) is a chronic and often lifelong disease
that can affect the hypothalamo-pituitary adrenal (HPA) axis at
any level (1). On a population level, AI is relatively uncommon,
with a prevalence of 93 to 144 per million (primary AI) and 150
to 280 per million (secondary AI, including those patients with
suppression of the HPA axis from chronic use of exogenous
corticosteroids in supra-physiological doses) (2). The effective
management of patients with AI, regardless of its etiology,
includes glucocorticoid replacement therapies (GRTs),
as well as mineralocorticoid replacement with primary AI.
Any interruption or insufficiency of GRT (such as during acute
infections, trauma or surgery) can manifest in acute deterioration
of clinical status (adrenal crisis), and threaten life (3).
Hydrocortisone (HC) is the most common form of GRT in
the UK and worldwide (4). Unfortunately, HC has a relatively
short half-life (around 120 min for total cortisol and 90 min for
free cortisol) (5, 6). Accordingly, most patients who take HC
require three doses per day, with the last dose often taken late
afternoon. The aim of any GRT regimen is to replicate the
normal circadian rhythm of serum cortisol which has its zenith
early in the morning just before waking (following a surge in the
1 to 2 h before waking), with levels gradually dropping during the
day and at night (7). Unfortunately, the use of standard HC
thrice daily results in three ‘mini-peaks’ of steroid following each
dose. Furthermore, there may be a period of 12 to 16 h (late
evening and during the night) where no HC is taken such that
steroid levels can drop precipitously, sometimes to dangerously
low levels in patients who have completely insufficient
endogenous glucocorticoid production. Finally, the short half-
life of HC can increase the vulnerability of patients with AI to
adrenal crisis, with delayed or missed doses. Compared to
controls with a normal HPA axis, patients with AI on HC
therapy have a higher standardized mortality rate (8, 9), and
an increased risk of weight gain and dysglycemia (10). The
pathogenesis of the increased mortality and morbidity of
patients with AI on HC therapy is incompletely understood,
and likely contributed to by multiple factors. One such factor
may stem from the mismatch between a typical daily steroid
profile of AI patients on multiple daily doses of HC therapy, and
a normal circadian rhythm of cortisol from an intact HPA axis.
More recently, an alternate form of HC therapy has become
available for the management of AI. Modified-release
Hydrocortisone (MR-HC) differs from HC in that its long
half-life enables once-daily administration, thereby reducing
the vulnerability from steroid insufficiency from delayed or
missed (multiple) doses (11, 12). MR-HC has a ‘dual-release’Abbreviations: AI, adrenal insufficiency; BMI, body mass index; BW, body
weight; DM, diabetes mellitus; GRT, glucocorticoid replacement therapy; HC,
hydrocortisone; HMRU, Human Metabolism Research Unit; HPA, hypothalamo-
pituitary adrenal; IQR, Inter-quartile range; LM, lean mass; MR-HC, modified-
release hydrocortisone; NS, non-significant; SD, standard deviation; SMR, sleeping
metabolic rate; T1D, type 1 diabetes mellitus; T2D, type 2 diabetes mellitus; TMR,
total metabolic rate; UHCW, University Hospitals Coventry and Warwickshire;
WBC, whole body calorimeter; WISDEM, Warwickshire Institute for the Study of
Diabetes, Endocrinology and Metabolism.
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released immediately following ingestion. This is then followed
by a slow and sustained release of HC from within the core of the
tablet (13). Compared with thrice daily HC, MR-HC provides a
more accurate reflection of the normal diurnal rhythm of cortisol
(12), but fails to match the physiological nocturnal rise of serum
cortisol (14). Furthermore, in a recent meta-analysis of the
current literature comparing HC with MR-HC in AI, our own
group showed that MR-HC associates with a more favorable
metabolic outcome, including reduced Body Mass Index (BMI)
and waist circumference, and improved glycemic control (15–
18). The underlying mechanism(s) that mediate the metabolic
improvements from MR-HC remain contentious and
incompletely understood. However, one intriguing hypothesis
relates to the possible metabolic effects of GRTs on clock gene
expression. Accordingly, Venneri and colleagues showed that in
patients with AI, thrice daily HC treatment associated with
disruption of the expression of certain circadian clock genes,
with restored clock gene expression within 3 months of switching
from HC to MR-HC therapy (19).
The emergence of MR-HC has provided an alternate once-daily
GRT treatment option in patients with AI, with superior replication
of the physiological profile of serum cortisol compared with the
more traditional option of multiple daily HC administration. It is
perhaps surprising, therefore, that the current literature lacks any
detailed metabolic comparisons between these two treatment
modalities in AI, other than the fairly blunt anthropometric
criteria of BMI and waist circumference (15). Our objective was
to explore the more detailed metabolic effects of MR-HC in patients
with AI following a switch from multiple daily HC therapy, in the
most highly-phenotyped study reported on to date.METHODS
Recruitment
We recruited adult patients (aged ≥18 years) with a confirmed
diagnosis of AI (n = 12) on an established regimen of HC,
administered twice or thrice daily. Recruitment (between August
2018 and April 2019) was from general endocrinology clinics at
the Warwickshire Institute for the Study of Diabetes,
Endocrinology and Metabolism (WISDEM) Centre, University
Hospitals Coventry andWarwickshire (UHCW), UK. Only those
patients who had been considered for switch to MR-HC for
clinical purposes were recruited, the reasons including need for
improved compliance with reduced pill burden, improved
corticosteroid coverage during the late evening and night and
patient preference. This was a pilot, observational study, and
therefore lacked any randomization or placebo arm. Exclusion
criteria included therapies (such as beta-adrenoceptor blockers)
that could interfere with body weight and energy expenditure.
All participants provided fully informed written consent prior to
enrolment into the study. All clinical investigations were
conducted in accordance with the guidelines in the declaration
of Helsinki. The study had specific approval from the West
Midlands Black Country Research Ethics Committee, UK.March 2021 | Volume 12 | Article 641247
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Following enrolment, each participant was invited to attend for a
baseline (‘HC’) metabolic assessment (whilst taking their usual
HC therapy), to include a fasting blood test, accurate measures of
body composition and 24-h continuous energy expenditure
through indirect calorimetry within a whole-body calorimeter
(WBC) at the Human Metabolism Research Unit (HMRU) at
UHCW. Details of theWBC have been described previously (20).
Following baseline metabolic assessment, each participant was
switched from their HC to MR-HC. Patients were converted
from HC to MR-HC, with the dose of MR-HC being equivalent
to the total daily dose of HC (rounding up to a multiple of 5 mg,
where necessary). Following 3 months of treatment with MR-
HC, each participant was invited to have a repeat (‘MR-HC’)
metabolic assessment on HMRU, to include the same measures
as indicated above. The repeat metabolic assessment marked the
conclusion of the study, and all participants were then switched
back to their usual HC therapies, and had usual clinical follow-up
thereafter within the Endocrine clinics at WISDEM center at
UHCW, UK. An outline summary of the research pathway is
shown in Figure 1.
Assessments of Body Composition and
Energy Expenditure
As indicated, each participant had two separate metabolic
assessments on HMRU: i) Baseline HC, and; ii) Repeat MR-
HC. For each participant, the two metabolic studies were
equivalent. On their assigned metabolic study day, participants
were required to arrive at HMRU for 8:00 AM in a fasting state
(no food or drink other than water for 8 h). Each participant was
required to take their HC (for baseline assessment) or MR-HCFrontiers in Endocrinology | www.frontiersin.org 3(for repeat assessment) at the usual times throughout each of the
metabolic study days (including any early morning doses prior to
travelling to HMRU). All participants were required to maintain
a stable isocaloric diet for 3-days prior to each metabolic study
day. Compliance with pre-metabolic study isocaloric diet was
verified using a self-completed three-day dietary questionnaire
(provided to each participant at enrolment). Furthermore, all
participants were required to avoid strenuous physical activity
and caffeine ingestion for a period of 24 h prior to each
metabolic study.
Each metabolic study commenced with acquisition of fasting
blood samples, followed by anthropometric assessment of body
composition (including fat and lean mass) using a BodPod
(Cosmed Inc., USA), a technique described previously and
based on air displacement plethysmography (21). Following a
fasting blood test and anthropometric assessment, each
participant was then invited to enter the WBC at 9:00 AM for a
24-h continuous assessment of energy expenditure. Whilst inside
the WBC, participants were requested to avoid physical activity.
Temperature (thermo-neutrality at 24°C) and relative humidity
(57%) were kept constant within the WBC throughout all
metabolic studies, to limit any potential for confounding
effects. Whilst inside the WBC, standard meals were provided
at pre-determined times that were kept constant throughout all
metabolic studies: Breakfast at 09:30hrs; Lunch at 12:15hrs;
Dinner at 17:00hrs, and; Evening snack at 20:00hrs.
Macronutrient content of each meal was kept constant, and
based on a standard diet of 35% fat, 15% protein, and 50%
carbohydrate. Each participant was requested to sleep between
22:00hrs and 07:00hrs the next day. Following 24 h within the
WBC, each participant was requested to exit the WBC at 09.00,FIGURE 1 | Summary of research pathway AI, adrenal Insufficiency; HC, hydrocortisone; HMRU, Human Metabolism Research Unit; MR-HC, modified release
hydrocortisone; WBC, whole body calorimeter.March 2021 | Volume 12 | Article 641247
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provision of breakfast, participants were able to go home.
Accurate minute-by-minute measurements of CO2 and O2
from air entering and leaving the WBC enabled continuous 24-h
assessment of energy expenditure through application of Weir’s
formula, described previously (20). Total Metabolic Rate (TMR)
was a cumulative assessment derived from energy expenditure
over the entire 24 h within the WBC. Sleeping metabolic rate
(SMR) was defined as mean average energy expenditure (kcal per
minute) during sleep (between 24.00hrs and 06.00hrs),
multiplied by 1,440 to enable direct comparison with TMR
over a 24-h period.
Assessment of Biochemistry
Fasting blood samples were obtained from each participant at
baseline HC and repeat MR-HCmetabolic assessments. Following
immediate spinning of each blood sample in a centrifuge, serum
was extracted and analyzed for HbA1c, lipid profile (total
cholesterol, low-density lipoprotein [LDL] cholesterol, high-
density lipoprotein [HDL] cholesterol and triglycerides) and
thyroid function parameters (Thyroid Stimulating Hormone
[TSH], free T4 and free T3). HbA1C was assayed using a
TOSOH G8 analyzer (high performance liquid chromatography
method), with a lower limit of detection of 3 mmol/mol. Lipid
parameters were assayed using a Roche/Hitachi cobas c system
(enzymatic, calorimetric method), with a lower limit of detection
of 0.1 mmol/L (3.86 mg/dl) for total cholesterol, and 0.1 mmol/L
(8.85 mg/dl) for triglyceride. Thyroid function parameters were
assayed using an Elecsys and a cobas e immunoassay analyzer.
Statistical Analyses
All statistical analyses were performed using Stata (version 15.0).
Normality for each variable was tested using Shapiro-Wilk test, with
a p-value of ≤0.05 deemed significant. For all normally-distributed
variables, paired-sample t-tests were used to compare data for each
participant from their baseline HC and repeat MR-HC metabolic
assessments. Using each participant as their own comparator with
the paired-sample t-test limits any confounding effects. For BMI
(the only non-normally distributed variable), the Wilcoxon Sign
Test was used for comparison baseline HC and repeat MR-HC
metabolic assessments, with a p-value of <0.05 deemed significant.
Data are reported as mean and standard deviation (SD) with 95%
confidence intervals for normally distributed variables. As a non-
normally distributed variable, BMI is reported as median and inter-
quartile range (IQR). As this was an exploratory study, it was not
possible to perform any a priori power calculations.RESULTS
Descriptive Data for the Cohort
We recruited 12 patients with AI from the WISDEM Centre,
UHCW. Of these 12 recruited participants, we excluded one of
them due to their admission to hospital with an adrenal crisis
during the 3-month study period. We also excluded another
participant who needed to take additional doses of HC (forFrontiers in Endocrinology | www.frontiersin.org 4clinical purposes) combined with their MR-HC during the 3-
month study period. We therefore included 10 participants in
our analyses. Of those participants included in the analyses, one
required an increased dose of thyroxine during the study,
although they remained biochemically euthyroid throughout.
(Sub-group analyses based on data that excluded this
individual participant made no appreciable difference to the
analyses or conclusions on body composition and energy
expenditure data from the whole cohort, presented below).
Of the 10 participants included in the analyses, mean age was
54.2 years (SD, 21.2 years), and there were four women and six
men. Administration of HC therapy was either thrice daily (n =
8) or twice daily (n = 2). Mean total daily dose of HC at
enrolment was 23 mg (SD 6.0). The types of AI included
primary (n = 6) and secondary (n = 4). One participant had
Type 2 Diabetes Mellitus (T2D), and one had Type 1 Diabetes
Mellitus (T1D), while the remaining 8 participants had no prior
or current history of Diabetes Mellitus (DM) and had confirmed
euglycemia. For the 4 participants with secondary AI, other
hormone replacements included thyroxine (dose range 100–
150 mcg per day; n = 3), desmopressin (n = 1), testosterone
(Tostran gel; n = 2), and oestrogen replacement therapies
(Loestrin, 20mg oestrogen, n = 1). For all participants on
hormone replacement therapies, these were adequately
replaced at enrolment, and throughout the entire study
(confirmed through relevant biochemical measurements at
baseline [HC] and follow-up [MR-HC] assessments). Two of
the participants with primary AI had concurrent hypothyroidism
with thyroxine replacement (adequately replaced). None of the
participants with primary AI had any other concurrent
endocr ine autoimmune comorbidi t ie s or hormone
replacement therapies.
Body Composition
Compared with baseline HC data, there was a significant
reduction in fat mass (mean: −3.2 kg; 95% CI: −6.0 to −0.4)
following 3 months of MR-HC therapy (mean [SD] baseline HC
fat mass vs repeat MR-HC fat mass: 31.9 kg [15.2] vs 28.7 kg
[12.8] respectively, P = 0.03). Compared with baseline HC data,
there was also a significant reduction in body fat percentage
(mean: −3.4%; 95% CI: −6.5 to −0.2) following 3 months of MR-
HC therapy (mean [SD] baseline HC body fat percentage vs
repeat MR-HC body fat percentage: 37.8% [13.3] vs 34.4% [10.6]
respectively, P = 0.04). All other measures of body composition,
including BMI, total body weight, and lean mass were equivalent
between baseline HC and repeat MR-HC metabolic assessments
(data shown in Table 1; Individual data for each of the
participants [n = 10] included in the analyses, including
descriptive data, are shown in Table 2).
Energy Expenditure
Compared with baseline HC data, there was a significant increase
in SMR (mean: +77 kcal/24 h; 95% CI: 10–146) following 3
months of MR-HC therapy (mean [SD] baseline HC SMR vs
repeat MR-HC SMR: 1,517 kcal/24 h [301] vs 1,594 kcal/24 h
[344] respectively, P = 0.03). When lean mass (LM) was factored
into SMR comparisons (using LM as a divisor), SMR/LM forMarch 2021 | Volume 12 | Article 641247
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equivalent. TMR and TMR/LM were equivalent between baseline
HC and repeat MR-HC metabolic assessments (data shown in
Tables 1 and 2).
Biochemistry
For all fasting serum biochemical analytes, there were no
significant differences between baseline (HC) and follow-up
(MR-HC) measurements (data shown in Table 1).DISCUSSION
We report on the most highly metabolically-phenotyped study to
date on comparison of the metabolic effects of HC versus MR-
HC in adult patients with AI. We demonstrate that compared
with HC therapy, switching to MR-HC for a period of 3 months
associates with significant metabolic benefits, includingFrontiers in Endocrinology | www.frontiersin.org 5reduction of fat mass and body fat percentage, and a significant
augmentation in SMR.
Assuming a mean average of 6 h sleep per night for each
participant and that the augmenting effect of MR-HC on SMR
occurs following its initiation, the cumulative effects of the
increased SMR during the 3-month study period would have
been approximately 1,800 kcal. If we assume that 3,500 kcal
equates to 0.45 kg of fat (22), then the increase in SMR with MR-
HC over a 3-month period would equate to approximately
0.25 kg of fat mass reduction. This represents a small
proportion (just 8%) of the overall reduction in fat mass
demonstrated with MR-HC therapy. Therefore, although
increased SMR may have contributed towards reduced fat mass
with MR-HC therapy, it seems unlikely that this effect alone
would have played a major role in reducing fat mass. Exploration
of other mechanisms (including appetite regulation) that
underlie reduced fat mass with MR-HC in AI, including
measurement of fat depot changes (through, for example,
Magnetic Resonance Imaging) should form a focus for future
research. The equivalence of SMR per unit of lean mass between
HC and MR-HC assessments suggests that the numerical
increase (albeit non-significant) in lean mass during the 3-
month period on MR-HC may underlie the overall increase in
SMR with MR-HC compared to that with HC.
To our knowledge, our study is the first report of a direct
comparison between HC and MR-HC therapies in AI using
WBC-based indirect calorimetry, and the first to show a
significant reduction in fat mass with MR-HC compared with
HC. Isidori and colleagues reported on a single-blind
randomized controlled trial in AI, with treatment options
including continued HC versus switch to MR-HC (16). At 24
weeks, there was a significant reduction in body weight for the
MR-HC group (mean treatment difference of 4 kg). There was
also an improvement in immune cell profiles, reduced
susceptibility to infections and improved quality of life in those
randomized to MR-HC compared to HC (16).
Prior studies on the effect of exogenous glucocorticoids on
energy expenditure have only focused on supra-physiological
replacement doses in patients without AI. In one such study on
healthy female volunteers who had 1 mg of betamethasone given
orally twice a day for 21 days, there was a significant mean increase
in fat mass of 1.5 kg (23). There was also a significant 26% increase
in total energy expenditure using a doubly-labeled water method
(23). The authors hypothesized that increased dietary energy
intake was the most likely explanation for the increase in fat
mass (despite increased energy expenditure), in response to supra
-physiological steroid doses in healthy volunteers (23). In a further
placebo-controlled study on healthy male volunteers,
supra-physiological administration of exogenous glucocorticoids
(intravenous infusion of methylprednisolone and oral
prednisolone) during a weight-maintenance diet resulted in
increased energy expenditure (measured through indirect
calorimetry) (24). There was also a significant increase in energy
intake in response to exogenous glucocorticoid administration.
The authors hypothesized a possible effect of glucocorticoids on
the central regulation of appetite (24).TABLE 1 | Body composition, energy expenditure and biochemistry at baseline
(HC) and follow-up (MR-HC) metabolic assessments.









BMI (kg/m2) 26.3 (3.7)a 25.6 (4.4)a NSb
Bodyweight (kg) 83.9 (17.2) 83.2 (18.2) NS
Fat Mass (kg) 31.9 (15.2) 28.7 (12.8) 0.03*
Body Fat (%) 37.8 (13.3) 34.4 (10.6) 0.04*
Lean Mass (kg) 52.1 (15.8) 54.6 (15.3) NS
Energy Expenditure
SMR
(kcal over 24 h)
1,517 (301) 1,594 (344) 0.03*
SMR/LM
(kcal/kg lean mass over
24 h)
30.1 (5.1) 29.7 (3.1) NS
TMR
(kcal over 24 h)
1,980 (390) 2,006 (399) NS
TMR/LM
(kcal/kg lean mass over
24 h)
39.5 (7.7) 37.5 (4.8) NS
Biochemistry (fasting serum samples)
HbA1C (mmol/mol) 43.1 (14.6) 41.5 (13.0) NS
Total cholesterol
(mmol/L)
4.7 (0.8) 4.9 (0.7) NS
HDL-cholesterol
(mmol/L)
1.5 (0.3) 1.5 (0.3) NS
LDL-cholesterol
(mmol/L)
2.7 (0.7) 2.7 (0.5) NS
Triglycerides (mmol/L) 1.3 (0.6) 1.5 (0.5) NS
Thyroid stimulating
hormone (mU/L)
1.7 (1.6) 1.5 (2.0) NS
Free T4 (pmol/L) 18.0 (3.0) 19.4 (3.2) NSData presented as mean and (standard deviation) unless otherwise indicated. a=median
and Inter-Quartile Range; Test statistic indicates paired-sample t-test comparison
between baseline and follow-up data unless otherwise indicated. b=Wilcoxon sign test
used as paired test.
BMI, Body Mass Index; HC, Hydrocortisone; HDL, High Density Lipoprotein; LDL, Low
Density Lipoprotein; LM, Lean Mass; MR-HC, Modified Release Hydrocortisone; NS,
Non-significant; SMR, Sleeping Metabolic Rate; TMR, total metabolic rate; *statistical
significance. Bold p-values indicate statistical significance.March 2021 | Volume 12 | Article 641247
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effects of supra-physiological doses of glucocorticoids in healthy
volunteers, and data from our own study on the metabolic effects of
GRTs in AI, are not directly comparable. However, it is possible that
differences in central appetite regulation between HC and MR-HC
can be extrapolated to AI, mediated through differences in
pharmacokinetic 24-h steroid profiles between these two forms of
GRT, and consequent differences in steroid exposure of the central
appetite centers. In one study, it was shown that compared with
dose-equivalent thrice-daily HC, MR-HC associates with a 20%
reduction in the area-under-the-curve for 24-h serum cortisol levels
(25). However, this change in overall steroid exposure needs to be
countered with a profile of serum cortisol that is more
physiologically replicable for MR-HC than for HC. Possible
changes in appetite and caloric intake between MR-HC and HC
in patients with AI remains entirely speculative, and should form a
focus for future research. Furthermore, future comparisons between
HC and MR-HC in AI should include groups with equivalent daily
exposure to GRT (to take account of the 20% reduction in the daily
corticosteroid exposure for MR-HC, compared with the equivalent
daily dose of HC (25)). This would require a dose adjustment for
MR-HC, to explore further the mechanisms that underlie the
metabolic differences between HC and MR-HC in AI.
One potential explanation for the metabolic benefits conferred
by MR-HC vs standard HC therapy in our study relates to
improved regulation of circadian clock mechanisms.
Glucocorticoids mediate interactions between central and
peripheral clocks in humans (26). Adrenal disorders such as AI
associate with dysregulation of clock synchronization through
disrupted circadian rhythms of cortisol (26). Furthermore,
evidence suggests that replicating a more physiological cortisol
rhythm through once-daily MR-HC rather than multiple dailyFrontiers in Endocrinology | www.frontiersin.org 6doses of HC confers additional benefits that include restoration of
immune function and improved inflammatory profile (16). These
benefits correlate with improved circadian gene expression profile
(19). Switching from multiple daily HC administration to once-
daily MR-HC associates with improved synchronization of clock
gene expression (26). Furthermore, improved glucocorticoid
exposure during the night with MR-HC may result in improved
synchronization of nocturnal autonomic pathways (27), and
optimized entrainment of hypothalamic and melanocortinergic
activities (26). We hypothesize that such nocturnal re-
synchronization of key neuro-autonomic and endocrine
pathways underlies, at least in part, the increase in SMR
observed following switch from HC to MR-HC therapy.
Our study has some limitations. Inclusion of a larger number of
participants would have provided better power for detection of
other possible metabolic differences between HC and MR-HC in
AI. However, our usage of the paired t-test with comparisons
of baseline HC and repeat MR-HC for each participant
would have limited any potentially confounding differences
between participants. Furthermore, we did not perform detailed
assessments of dietary intake, appetite, and physical activity that
may have provided more insights into the improved fat mass with
MR-HC. Furthermore, our study was of a relatively short duration,
and future studies should focus on the possible longer-term
metabolic effects (beyond 3 months) of MR-HC in AI, and the
durability of any early metabolic changes such as reduced fat mass
and augmented SMR. It was not possible to perform sub-group
analyses on our data due to a relative lack of power.With inclusion
of larger numbers of participants, with a greater range of BMI,
future studies should explore any predictors (such as baseline BMI
or fat mass) for the metabolic benefits of MR-HC in patients with




































2 66 F P 35 3 35 −17.7 +9.4 +11.0 +10.6 Atrial Fibrillation
3 66 M P 15 2 20 −12.7 +27.3 +11.8 +3.3 Hypothyroidism
Obesity;
Asthma
4 37 F P 22.5 3 25 −22.2 +12.4 +2.4 +0.7 Hypothyroidism
5 26 M P 20 3 20 −1.9 +2.5 +5.8 +3.3 -
6 54 M P 25 3 25 −1.9 −1.6 +3.7 −4.8 Hypertension
Depression
7 21 F S 17.5 3 20 −22.2 +12.4 −4.0 −2.2 -
8 87 M S 20 3 20 +2.2 −2.8 +18.5 +6.1 -
9 70 M S 25 3 25 −9.8 +0.9 0 −4.5 Hypertension
10 68 F S 20 3 20 +2.2 0 −4.5 −5.3 T1D
DyslipidaemiaMarch 2021 | Volume 12a= Data presented as a percentage of baseline values from HC metabolic study.
AI, adrenal insufficiency; BMI, body mass index; CKD, chronic kidney disease; F, female; FM, fat mass; HC, hydrocortisone; LM, lean mass; M, male; MR-HC, modified release
hydrocortisone; P, primary; S, secondary; SMR, sleeping metabolic rate; T1D, type 1 diabetes mellitus; T2D, type 2 diabetes mellitus; TMR, total metabolic rate.| Article 641247
Bannon et al. Benefit of MRHC Versus HC in AIsingle crossover design), our study lacked any placebo arm or
randomization, with the possibility (although unlikely) of an order
effect. Finally, as the HC and MR-HC metabolic assessments
occurred 3 months apart, seasonal differences may have
potentially confounded our metabolic data.
To summarize, we demonstrate that in adult patients with AI
who take multiple daily doses of HC therapy, switching to MR-
HC results in a significant reduction in body fat and augmentation
of SMR within 3 months. It is possible that increased SMR in
response to MR-HC may contribute towards a favorable effect on
fat mass, although this mechanism is unlikely to play a major role.
The factors that underlie the metabolic benefits of MR-HC
compared with HC in patients with AI should form a focus for
future studies in larger numbers of participants, with more
detailed phenotyping (including data on dietary intake, physical
activity, fluid status, blood pressure, muscle mass, fat distribution,
and glycemic control) and for a longer duration. Given the
importance of obesity and metabolic dysfunction as a modern-
day global health issue that underlies much 21st century chronic
ill-health (including in patients with AI), any improvement in fat
mass and metabolic status is likely to confer substantial clinical
benefits on a population level that would likely improve overall
metabolic health and health economic efficiency. Our data
support the use of MR-HC in adult patients with AI. Such an
approach for the management of AI should be considered in
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